

Seroconversion:	no	yes	<i>p</i>
n	13	6	
Age (mean (SD))	65.89 (10.85)	64.52 (10.43)	0.799
Gender: female (%)	10 (76.9)	3 (50.0)	0.320
<b>Diagnosis n (%)</b>			0.503
IgG4-related Disease	1 (7.7)	1 (16.7)	
Connective Tissue Disease	4 (30.8)	0 (0.0)	
Rheumatoid Arthritis	6 (46.2)	3 (50.0)	
Vasculitis	2 (15.4)	2 (33.3)	
Peripheral B cells, absolute (median [IQR])	0.00 [0.00, 0.00]	16.00 [3.75, 38.75]	<b>0.003</b>
Detectable B cells n (%)	2 (15.4)	5 (83.3)	<b>0.019</b>
IgG (median [IQR]) mg/dL	802 [654, 961]	695 [595, 897]	0.399
IgM (median [IQR]) mg/dL	51 [26, 64]	37 [30, 52]	0.512
Months between RTX and Vaccination (mean (SD))	4.3 (1.6)	6.5 (1.1)	<b>0.006</b>
Days between Vaccine and Laboratory assessment (mean (SD))	16.9 (11.4)	14.3 (8.4)	0.638
<b>Concomitant Medication n (%)</b>			
Any csDMARD	7 (53.8)	3 (50.0)	1.000
Methotrexate	5 (38.5)	0 (0.0)	0.128
Mycophenolate Mofetil	1 (7.7)	0 (0.0)	1.000
Hydroxychloroquine	0 (0.0)	2 (33.3)	0.088
Azathioprine	1 (7.7)	1 (16.7)	1.000
Leflunomide	0 (0.0)	1 (16.7)	0.316
Sulfasalazine	0 (0.0)	1 (16.7)	0.316
Immunoglobulin therapy	0 (0.0)	0 (0.0)	
Prednisone	5 (38.5)	1 (16.7)	0.605
<b>Vaccine n (%)</b>			0.115
mRNA-1273	2 (15.4)	1 (16.7)	1.000
BNT162b2	11 (84.6)	5 (83.3)	
SARS Cov2-S Antibodies U/ml (median [IQR])	0.0 [0.0, 0.0]	8.0 [3.5, 26.3]	<b>&lt;0.001</b>
Mean T cell response per SFCs/10 <sup>6</sup> PBMCs	10.27 (12.00)	17.88 (13.73)	0.236

**Supplemental Table 4:** Patient characteristics of SARS-CoV-2-specific T cell non-responders stratified by seroconversion